Small molecular agents against MERS-CoV infection / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1520-1526, 2015.
Artículo
en Chino
| WPRIM
| ID: wpr-320048
ABSTRACT
Middle East respiratory syndrome coronavirus (MERS-CoV) has caused outbreaks of SARS-like disease with 35% case-fatality rate, mainly in the Middle East. A more severe outbreak of MERS occurred recently in the Republic of Korea, where 186 people contracted the infections, causing great concern worldwide. So far, there has been no clinically available drug for the treatment of MERS-CoV infection. The potential drugs against MERS-CoV mainly consist of monoclonal antibodies, peptides and small molecular agents. Small molecular agents have an advantage of easier synthesis, lower cost in production and relatively higher stability. There is better chance for those candidates to gain a quick development. This article reviews the progress of developing small molecular MERS-CoV agents.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Antivirales
/
Farmacología
/
Diseño de Fármacos
/
Infecciones por Coronavirus
/
Quimioterapia
/
Coronavirus del Síndrome Respiratorio de Oriente Medio
/
Anticuerpos Monoclonales
Límite:
Humanos
Idioma:
Chino
Revista:
Acta Pharmaceutica Sinica
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS